Skip to Content

Tag: budesonide


Specialty Providers

ASP: Budesonide reverses course

December 11, 2013HME News Staff

BALTIMORE - When it comes to nebulizer medication pricing, one quarter you're up; another quarter you're down.Average sales price (ASP) figures for the first quarter of 2014 revealed a decrease for budesonide (J7626) of nearly 35 cents to $5.60 per dose. That's in contrast to the previous quarter, when the drug increased 85 cents.The only other drugs to see increases for the upcoming quarter: brand names Brovana (J7605) and Perforomist (J7606), which increased 22 cents and 6 cents, respectively....

albuterol, average sales price, brovana, budesonide, ipratropium, neb meds, perforomist


Read Full Articlered right arrow icon

Specialty Providers

ASP: Winners, losers, audits

October 25, 2013Theresa Flaherty, Managing Editor

BALTIMORE - With few exceptions, the average sales price (ASP) figures for nebulizer medications don't change much from quarter to quarter. That doesn't mean the market is stagnant, says Wayne Vega, senior vice president of the Inhalation Drug Group. He recently offered HME News his take on the fourth quarter numbers—and the market.WinnersBudesonide (J7626) increased 85 cents, to $5.95 per dose. The entry of another generic version of the drug into the market earlier this year didn't have the...

average sales price, budesonide, neb-meds


Read Full Articlered right arrow icon

News

In brief: CMS delays F2F rule again, Golden endorses Reverie

September 13, 2013HME News Staff

BALTIMORE - CMS had no choice but to delay—for the second time—enforcement of its face-to-face rule until sometime in 2014, say industry stakeholders. “We just haven't seen any further education,” said Kim Brummett, senior director of regulatory affairs for AAHomecare. In its Sept. 9 announcement, CMS said the delay is needed to give providers and healthcare practitioners time to establish necessary protocols to fully comply with the rule. The face-to-face requirement took...

a/r allegiance group, budesonide, european oxygen market, face to face, FMCSA, golden technologies, Maddak, medbill, Medicare, OIG


Read Full Articlered right arrow icon

Also Noted

ASP: Budesonide gets big boost

September 10, 2013HME News Staff

BALTIMORE - Things are looking up for several respiratory medications in the latest average sales price (ASP) figures. For the fourth quarter 2013, budesonide (J7626) took the biggest leap, up 85 cents to $5.95 per dose. Also getting an increase: brand name drugs Brovana (J7605) and Perforomist (J7606), which saw increases of 12 cents and nearly 39 cents per dose. Pricing stayed relatively flat for albuterol (J7613) and ipratropium (J7644) were both hovering around 12 cents per dose.

albuterol, ASP figures, budesonide, neb-meds


Read Full Articlered right arrow icon

Specialty Providers

Prices, audits stay the course

April 23, 2012Theresa Flaherty, Managing Editor

BALTIMORE - Brand-name Brovana took a hit in the latest average sales price (ASP) figures for nebulizer medications, but otherwise there were few major changes.The long-acting beta agonist Brovana (J7605) decreased 24 cents to $5.11 per dose in the latest figures, released in March.Between the lower reimbursement and a price increase from the manufacturer, you won't see many providers supplying the drug, said Sam Jarczynski, who blames market consolidation for the change.“There are so few respiratory...

albuterol, average sales prices, brovana, budesonide, neb-meds, perforomist


Read Full Articlered right arrow icon